Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window of Opportunity Clinical Trial

PURPOSE: Ras/MEK/ERK pathway activation is common in oral cavity squamous cell carcinoma (OCSCC). We performed a neoadjuvant (pre-operative) trial to determine biomarker and tumor response of OCSCC to MEK inhibition with trametinib. PATIENTS AND METHODS: Patients with Stage II–IV OCSCC received tram...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Uppaluri, Ravindra, Winkler, Ashley E., Lin, Tianxiang, Law, Jonathan H., Haughey, Bruce H., Nussenbaum, Brian, Paniello, Randal C., Rich, Jason T., Diaz, Jason A., Michel, Loren P., Wildes, Tanya M., Dunn, Gavin P., Zolkind, Paul, Kallogjeri, Dorina, Piccirillo, Jay F., Dehdashti, Farrokh, Siegel, Barry A., Chernock, Rebecca D., Lewis, James S., Adkins, Douglas R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5509449/
https://ncbi.nlm.nih.gov/pubmed/28151720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1469
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados